Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001948038 | SCV002188173 | uncertain significance | not provided | 2023-04-25 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 10 of the GABRA2 protein (p.Met10Thr). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant  is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 1417022). This variant has not been reported in the literature in individuals affected with GABRA2-related conditions. This variant is present in population databases (rs200327122, gnomAD 0.04%). |
Ambry Genetics | RCV002556438 | SCV003536919 | uncertain significance | Inborn genetic diseases | 2021-06-03 | criteria provided, single submitter | clinical testing | The c.29T>C (p.M10T) alteration is located in exon 1 (coding exon 1) of the GABRA2 gene. This alteration results from a T to C substitution at nucleotide position 29, causing the methionine (M) at amino acid position 10 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003134245 | SCV003816261 | uncertain significance | Developmental and epileptic encephalopathy, 78 | 2021-12-28 | criteria provided, single submitter | clinical testing |